test directorySearch Results

Click here to search again.

Test Name:
IGH/BCL2 t(14;18) Translocation by FISH, Blood or Bone Marrow

  • TMF No:
  • Performance Lab Name:
    TMF Flow Cytometry / Molecular Pathology
  • Test Mnemonic:
    T14;18 BBM
  • CPT Code:
    88271x2; 88275
  • Also Known As:
    Follicular Lymphoma; t(14;18)(q32;q21) by Fluorescence in situ hybridization (FISH)
  • Patient Prep:
    NOTICE: Genetic tests are often subject to limited coverage and/or prior-authorization requirements. Consult the patient’s medical insurance provider before ordering this test.
  • Spec Collect:
    Lavender top (EDTA) or Green top (sodium heparin) tube; whole blood or bone marrow. Mix by inverting tube 8 times.
  • Spec Process:
    Transport 5 mL whole blood (Min: 2 mL). OR 2 mL bone marrow (Min: 1 mL).
  • Spec Store Transport:
    Room temperature or refrigerated.
  • Spec Stability:
    Room temperature: 72 hours
    Refrigerated: 1 week
    Frozen: Unacceptable
  • Spec Reject:
    Frozen, clotted, or grossly hemolyzed specimens.
  • Spec Remarks:
    Bone marrow smears are also acceptable (3 slides preferred; 1 slide minimum)
  • Methodology:
    Fluorescence in Situ Hybridization (FISH)
  • Clinical Significance:

    Follicular lymphoma (FL) is one of the most common non-Hodgkin’s lymphomas of B cells and is closely associated with a t(14;18) translocation. Detection of t (14;18), which is present in 70–95 percent of FL, is often helpful in establishing a diagnosis of follicular lymphoma and monitoring disease progression.

    The distinction of follicular lymphoma from other lymphomas is important and provides prognostic and therapeutically relevant information.

  • Interpretive Data:

    This test was developed and its performance was established and confirmed by the SBMF. This test is not cleared or approved by the U.S. FDA. This test is used for clinical purposes and should not be regarded as investigational or for research. The South Bend Medical Foundation is authorized under Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing.

    This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.

  • Day Run:
  • Time Reported:
  • Test Type: